An acquisition means integration work is about to be scoped. Fundz scores the company against what you sell, and says why it matched.See it live →
Aethlon Medical merges with North Immunology
PUBLIC · AEMDSep 17, 2026•about 2 hours ago
Acquiring Company
Aethlon Medical
Acquired Company
North Immunology
San DiegoAustinBiotechnologyHealth CareMedicalTherapeuticsBiotechnologyHealth CareTherapeutics
Description
Aethlon Medical has announced a definitive merger agreement with North Immunology in an all-stock transaction. The merger aims to advance the development of NOR-101, a bispecific antibody for atopic dermatitis. The combined entity will operate as North Immunology, Inc. and is set to trade on the Nasdaq Capital Market under a new ticker symbol. This merger also includes a $180 million private placement to fund their operations.
Company Information
Company
Aethlon Medical
Location
San Diego, California, United States
About
Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.
Additional information can be found at www.AethlonMedical.com.
Don't miss Aethlon Medical's next move
Get an email the moment Aethlon Medical makes an acquisition, hires an exec, or expands, usually minutes after it happens.
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed
Frequently asked
Who acquired North Immunology?
North Immunology was acquired by Aethlon Medical, based in San Diego. The deal was reported on September 17, 2026. Aethlon Medical is publicly traded (AEMD) and operates in Biotechnology.
When did Aethlon Medical acquire North Immunology?
Aethlon Medical's acquisition of North Immunology was reported on September 17, 2026. Aethlon Medical has announced a definitive merger agreement with North Immunology in an all-stock transaction. The merger aims to advance the development of NOR-101, a bispecific antibody for atopic dermatitis. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does North Immunology do?
North Immunology is a privately held biotechnology company developing bispecific antibodies aimed at treating immune and inflammatory diseases. It is privately held, operating in Biotechnology, and is based in Austin.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
San Diego